Gilead Sciences (GILD) Earns Media Impact Score of 0.17

News articles about Gilead Sciences (NASDAQ:GILD) have trended somewhat positive on Sunday, according to Accern. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Gilead Sciences earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 46.4363176279108 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the news articles that may have impacted Accern Sentiment’s analysis:

How to Become a New Pot Stock Millionaire

Gilead Sciences stock traded down $2.73 during mid-day trading on Friday, hitting $72.84. The stock had a trading volume of 8,976,615 shares, compared to its average volume of 7,231,907. Gilead Sciences has a 52-week low of $63.76 and a 52-week high of $89.54. The company has a quick ratio of 2.67, a current ratio of 2.74 and a debt-to-equity ratio of 1.53. The stock has a market capitalization of $95,418.06, a PE ratio of 20.93, a P/E/G ratio of -1.67 and a beta of 1.24.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $5.71 billion. During the same quarter in the previous year, the business earned $2.70 earnings per share. The company’s revenue was down 18.7% on a year-over-year basis. analysts expect that Gilead Sciences will post 6.21 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be paid a $0.57 dividend. The ex-dividend date is Thursday, March 15th. This represents a $2.28 annualized dividend and a dividend yield of 3.13%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s payout ratio is currently 65.52%.

Several equities research analysts have commented on GILD shares. ValuEngine raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. Credit Suisse Group set a $80.00 target price on Gilead Sciences and gave the stock a “hold” rating in a report on Wednesday, January 3rd. Leerink Swann dropped their target price on Gilead Sciences from $86.00 to $83.00 and set a “market perform” rating on the stock in a report on Wednesday, February 7th. Vetr raised Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 target price on the stock in a report on Monday, February 19th. Finally, Barclays reissued an “overweight” rating and issued a $95.00 target price (up from $90.00) on shares of Gilead Sciences in a report on Tuesday, March 6th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company’s stock. Gilead Sciences presently has an average rating of “Buy” and a consensus target price of $88.61.

In related news, CFO Robin L. Washington sold 5,000 shares of the company’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $80.31, for a total transaction of $401,550.00. Following the completion of the sale, the chief financial officer now owns 23,749 shares in the company, valued at $1,907,282.19. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director John Francis Cogan sold 5,833 shares of the company’s stock in a transaction on Friday, March 16th. The shares were sold at an average price of $80.09, for a total value of $467,164.97. Following the sale, the director now owns 58,452 shares of the company’s stock, valued at approximately $4,681,420.68. The disclosure for this sale can be found here. Insiders sold 436,101 shares of company stock valued at $34,541,560 in the last 90 days. Company insiders own 1.30% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Gilead Sciences (GILD) Earns Media Impact Score of 0.17” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3300365/gilead-sciences-gild-earns-media-impact-score-of-0-17.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Lydall, Inc.  Holdings Boosted by Wells Fargo & Company MN
Lydall, Inc. Holdings Boosted by Wells Fargo & Company MN
Orchid Island Capital  Stock Rating Upgraded by Zacks Investment Research
Orchid Island Capital Stock Rating Upgraded by Zacks Investment Research
Red Hat Software  Price Target Increased to $185.00 by Analysts at Deutsche Bank
Red Hat Software Price Target Increased to $185.00 by Analysts at Deutsche Bank
Morgan Stanley Lowers Scorpio Bulkers  Price Target to $8.50
Morgan Stanley Lowers Scorpio Bulkers Price Target to $8.50
Jefferies Group Initiates Coverage on Summit Materials
Jefferies Group Initiates Coverage on Summit Materials
Two Sigma Investments LP Invests $291,000 in HFF
Two Sigma Investments LP Invests $291,000 in HFF


© 2006-2018 Ticker Report. Google+.